Evidence map›Paper›PMID 40978575›Full record

ArticleInternational journal of cardiology. Cardiovascular risk and prevention2025

Cancer as a novel risk factor for major cardiovascular adverse events in secondary prevention.

Renzo Melchiori, Sara Diaz Saravia, Pablo M Rubio, Lucas Szlaien, Romina Mouriño, Martin O'Flaherty, Manglio Rizzo, Alejandro Hita

Abstract read
In one paragraph

Article in International journal of cardiology. Cardiovascular risk and prevention, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Renzo MelchioriDepartment of Cardiology and Echocardiography, Hospital Universitario Austral, Austral University, Derqui-Pilar, Buenos Aires, Argentina.
Sara Diaz SaraviaDepartment of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Pablo M RubioInterventional Cardiology, Medstar Washington Hospital Center, Washington, D.C, USA.
Lucas SzlaienDepartment of Cardiology, Hospital Posadas, Buenos Aires, Argentina.
Romina MouriñoDepartment of Medicine, Loyola University Medical Center, Chicago, USA.
Martin O'FlahertyDepartment of Public Health, Policy and Systems, University of Liverpool, Liverpool, United Kingdom.
Manglio RizzoCancer Immunobiology Laboratory, Instituto de Investigaciones en Medicina Traslacional, Universidad Austral-Consejo Nacional de Investigaciones Cientificas y Tecnologicas (CONICET), Buenos Aires, Argentina.
Alejandro HitaDepartment of Cardiology and Echocardiography, Hospital Universitario Austral, Austral University, Derqui-Pilar, Buenos Aires, Argentina.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The inflammatory mechanisms of cancer can be associated with atherosclerosis development and progression. Although the incidence of events in secondary prevention following a first acute coronary syndrome is poorly documented. Methods: A retrospective cohort study including patients who underwent a coronary angiography for first Acute Coronary Syndrome (ACS), and without prior history of Major Cardiovascular Events (MACE) from 2008 to 2023 was analyzed. Included patients were grouped according to the absence or presence of cancer: G1 non-oncologic, and G2 oncologic (either prior or current history). We compared the incidence rate ratio of MACE within 3 years after ACS between groups Time-to-event analysis was conducted through proportional Cox regression analysis, estimating hazard ratio, and corresponding 95 % confidence intervals (95 % CI). Results: Of 937 patients who underwent a coronary angiography, 787 patients were included, of which 88.7 % (n = 698) presented without cancer. Over a median follow-up time of 48 months [IQR = 14-72], the incidence rate of MACE was 4.4 cases per 1000 patients/months of follow-up (n = 173 MACE events). When comparing both groups, the incidence rate ratio of MACE was 1.9 (95 % CI 1.24-2.99), significantly increased in the cancer group (P = 0.0032). Cancer was an independent predictor of MACE after adjustment for traditional cardiovascular risk factors (HR 1.84, 95 % CI 1.19-2.85; P = 0.006). Conclusions: Patients with cancer represent a novel independent risk factor for MACE, even following secondary preventive therapies. These results highlight future endpoints for cardiovascular prevention and further public health interventions in this population.

Indexed as

CancerCoronary artery diseaseRisk factorSecondary prevention

Identifiers

PMID40978575
PMCPMC12445231

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.